

- SP.01.0 1 INCREASED COL5 ALPHA 2 MRNA EXPRESSION IN FIBROBLAST CULTURES FROM SYSTEMIC SCLEROSIS PATIENTS CAN EXPLAIN REMODELING IN THIS DISEASE. 2**  
P. Martin, W.R. Teodoro, J. de Morais, M.L.H. Kathayama, S. Carrasco, A.P.P. Velosa, R.G. Marangoni, C. Goldeinstein-Schainberg, R.B.C. Souza, V.L. Capelozzi, PHD. Yoshinari
- SP.1.2 TYPE V COLLAGEN NASAL TOLERANCE DECREASES PULMONARY COLLAGEN MRNA AND TGF BETA EXPRESSION IN EXPERIMENTAL MODEL OF SYSTEMIC SCLEROSIS 3**  
A.P.P. Velosa, W.R. Teodoro, M.L.H. Kathayama, J. de Morais, M.C. Medeiros, E.R. Parra, V.L. Capelozzi, N.H. Yoshinari
- SP.01.0 3 COLLAGEN V-INDUCED NASAL TOLERANCE DOWNREGULATES CUTANEOUS REMODELLING IN EXPERIMENTAL SYSTEMIC SCLEROSIS 4**  
A.P.P. Velosa, W.R. Teodoro, A. Santos-Filho, A.G. Santos, M.R. Callado, M.B.G. Vendramini, C. Bueno, E.R. Parra, V.L. Capelozzi, N.H. Yoshinari
- SP.01.0 4 UPREGULATED EXPRESSION OF VERSICAN IN MONOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS: ROLE IN AMPLIFICATION OF MONOCYTES-CHEMOATTRACTANT PROTEIN-1 (MCP-1) ACTIVITY AT SITE OF FIBROSIS 9**  
H. YASUOKA, A. Masuda, Y. Yamaguchi, T. Satoh, M. Kuwana
- SP.01.0 5 ROSIGLITAZONE ALLEVIATES THE PERSISTENT FIBROTIC PHENOTYPE OF LESIONAL SKIN SCLERODERMA FIBROBLASTS 11**  
S. XU, M. Eastwood, R. Stratton, C.P. Denton, D. Abraham, A. Leask
- SP.01.0 6 MORPHOMETRIC EVALUATION OF LYMPHATIC AND BLOOD VESSELS IN SCLERODERMA SKIN 18**  
E. WEBER, A. Rossi, F. Sozio, P. Sestini, E.A. Renzoni, K. Khan, C.P. Denton, D.J. Abraham

<b>SP.01.0</b> <b>7</b>	<b>INDUCIBLE COSTIMULATOR LIGAND (ICOSL) REGULATES TISSUE FIBROSIS INDEPENDENTLY OF THE ICOS-ICOSL PATHWAY IN MOUSE MODELS OF SYSTEMIC SCLEROSIS</b>	<b>28</b>
	C. TANAKA, M. Hasegawa, M. Fujimoto, Y. Hamaguchi, S. Sato, K. Takehara	
<b>SP.01.0</b> <b>8</b>	<b>EFFECTS OF THE IMMUNOSUPPRESSANT RAPAMYCIN ON HUMAN <math>\alpha 2(I)</math> COLLAGEN IN SCLERODERMA FIBROBLASTS</b>	<b>30</b>
	Z. TAMAKI, Y. ASANO, M. KUBO, H. IHN, N. YAZAYA, R. ASHIDA, M. TOMMITA, T. KAWASHIMA, K. TAMAKI, S. SATO	
<b>SP.1.09</b>	<b>STIMULATORY AUTOANTIBODIES AGAINST PDGF RECEPTOR IN A LARGE COHORT OF ITALIAN SCLERODERMA PATIENTS.</b>	<b>32</b>
	T. SPADONI, S. SVEGLIATI, L. DEGENNARO, G. MORONCINI, R. BAGNATI, D. AMICO, M. ROCCHI, G. POMPONIO, E. AVVEDIMENTO, A. GABRIELLI	
<b>SP.01.1</b> <b>0</b>	<b>DETECTION OF STIMULATORY ANTI-PDGF RECEPTOR AUTOANTIBODIES BY BIOASSAYS BASED ON DIFFERENT CELL LINES</b>	<b>33</b>
	S. SVEGLIATI, T. SPADONI, L. DEGENNARO, G. MORONCINI, M. ROVINELLI, E. AVVEDIMENTO, A. GABRIELLI	
<b>SP.1.11</b>	<b>EPIDERMAL CELLS FROM SYSTEMIC SCLEROSIS PATIENTS PROMOTE FIBROBLAST ACTIVATION VIA IL-1&lt;ALPHA&gt;</b>	<b>35</b>
	R. STRATTON, N. ADEN, X. SHIWEN, C. BLACK, C. DENTON, D. ABRAHAM	
<b>SP.01.1</b> <b>2</b>	<b>ALTERED FIBROBLAST IMMUNE RECOGNITION SIGNALING VIA TOLL-LIKE RECEPTORS IN SYSTEMIC SCLEROSIS</b>	<b>74</b>
	K. OOKA, F. Fang, D. Melichian, S. Bhattachyy, J. Wei, J. Varga	
<b>SP.01.1</b> <b>3</b>	<b>DEVELOPMENT OF A SOLID PHASE BINDING ASSAY FOR DETECTION OF CONFORMATIONAL ANTI-PDGFR AUTOANTIBODIES IN THE SERUM OF PATIENTS AFFECTED BY SCLERODERMA</b>	<b>89</b>
	G. MORONCINI, G. NACCI, M. CUCCIOLONI, C. PAOLINI, A. GRIECO, C. TONNINI, E.V. AVVEDIMENTO, A. FUNARO, A. GABRIELLI	
<b>SP.1.14</b>	<b>EFFECTS OF ENDOTHELIN-1 AND GONADAL HORMONES ON FIBROGENESIS OF CULTURED HUMAN NORMAL AND SCLERODERMA SKIN FIBROBLASTS</b>	<b>93</b>
	S. SOLDANO, R. Brizzolara, P. Montagna, C. Pizzorni, S. Paolino, A. Parodi, G. Gianotti, B. Villaggio, B. Serio, A. Sulli, M. Cutolo	

- SP.01.1 5 ENVOLVEMENT OF PULMONARY ARTERY IS ALSO OBSERVED IN SYSTEMIC SCLEROSIS ANIMAL MODEL INDUCED BY COLLAGEN V IMMUNIZATION IN RABBITS. 105**  
S. Carrasco, W.R. Teodoro, P. Martin, C. Prizon, C. Goldenstein-Schainberg, A.P.P. Velosa, V.L. Capelozzi, N.H. Yoshinari
- SP.01.1 6 BIOCHEMICAL AND MOLECULAR PROFILE OF COLLAGEN V IN SYSTEMIC SCLEROSIS PATIENTS IS DIFFERENT FROM IDIOPATIC FIBROSIS AND JUSTIFY CUTANEOUS THICKNESS. 106**  
W.R. Teodoro, P. Martin, F. Braga, J. Morais, A.P.P. Velosa, S. Carrasco, R.B.C. Souza, C. Goldenstein-Schainberg, M.L.H. Katayama, V.L. Capelozzi, N.H. Yoshinari
- SP.01.1 7 ABNORMAL EXPRESSION OF TYPE V COLLAGEN CAN EXPLAIN CUTANEOUS FIBROSIS AND OCCURS EARLY IN SYSTEMIC SCLEROSIS. 107**  
P. MARTIN, W. R. TEODORO, F. BRAGA, A.P.P. VELOSA, S. CARRASCO, R.B.C. SOUZA, E.R. PARRA, C. GOLDEINSTEIN-SCHAINBERG, M.N. SOTTO, V.L. CAPELOZZI, N.H. YOSHINARI
- SP.01.1 8 INCREASED EXPRESSION OF NATURAL KILLER CELL SURFACE RECEPTORS ON CD8+ T CELLS OF SYSTEMIC SCLEROSIS PATIENTS 111**  
R.G. MARANGONI, S. CARRASCO, M.H. GAMBIM, C. GOLDENSTEIN-SCHAINBERG, R.B.C. SOUZA
- SP.01.1 9 EXPERIMENTAL MODEL OF SYSTEMIC SCLEROSIS INDUCED BY COLLAGEN V REPRODUCES EXTRA AND INTRAPULMONARY ARTERY SYSTEM DYSFUNCTION. 112**  
R.G. MARANGONI, E.R. PARRA, H.V. BARBEIRO, A.P.P. VELOSA, V.G. SORIANO, W.R. TEODORO, V.L. CAPELOZZI, N.H. YOSHINARI
- SP.01.2 0 INTEGRIN BETA1 EXPRESSION BY FIBROBLASTS IS REQUIRED FOR TISSUE REPAIR IN VIVO 118**  
S. LIU, X. Shi-wen, T. Krieg, DJ. Abraham, A. Leask
- SP.01.2 1 TH17S AND CD4+CD25+ TREGS LYMPHOCYTES IN THE PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS 121**  
M. LI, N. JIANG, D. XU, Y. HOU, Q. WANG, X. ZENG
- SP.01.2 2 TELOMERE LENGTHS OF PERIPHERAL BLOOD CD4+ T CELLS IN SYSTEMIC SCLEROSIS 123**  
E. LEE, JA. Park, JY. Choi, JH. Kim, HR. Choi, HR. Kim, RM. Cawthon

<b>SP.01.2</b> <b>3</b>	<b>PREDOMINANCE OF CENTRAL MEMORY SUBSETS IN PERIPHERAL BLOOD T CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS</b>  E. LEE, JA. Park, HR. Kim, JH. Kim, EY. Lee, YJ. Lee, YW. Song	<b>124</b>
<b>SP.01.2</b> <b>4</b>	<b>RAC INHIBITION REVERSES THE PERSISTENT FIBROTIC PHENOTYPE OF SCLERODERMA DERMAL FIBROBLASTS</b>  A. LEASK, S. Liu, X. Shiwen, C. Denton, D. Abraham	<b>125</b>
<b>SP.01.2</b> <b>5</b>	<b>ANTI-FIBROTIC EFFECTS OF PROTEASOME INHIBITION ON BLEOMYCIN-INDUCED EXPERIMENTAL SCLERODERMA</b>  S. KOCA, M. OZGEN, I. OZERCAN, F. DAGLI, B. USTUNDAG, A. ISIK	<b>134</b>
<b>SP.01.2</b> <b>6</b>	<b>SELECTIVE INHIBITION OF TGF<math>\beta</math> SIGNALLING IN RESIDENT PULMONARY FIBROBLASTS BLOCKS FIBROCYTE RECRUITMENT AND MYOFIBROBLAST DIFFERENTIATION AFTER ACUTE LUNG INJURY</b>  K. KHAN, R. HOYLES, E. DERRETT-SMITH, X. SHIWEN, D. ABRAHAM, CP. DENTON	<b>141</b>
<b>SP.01.2</b> <b>8</b>	<b>INTERLEUKIN-33 AND ITS RECEPTOR ST2 MAY SERVE AS 'ALARMIN' SYSTEM OF THE PROGRESSING DAMAGE TO THE SKIN AND VISCERAL ORGANS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS</b>  M. Manetti(), V. Liakouli, AF. Milia, P. Cipriani, S. Guiducci, G. Benelli, R. Giacomelli, L. Ibba-Manneschi, M. Matucci-Cerinic	<b>154</b>
<b>SP.01.2</b> <b>9</b>	<b>INHIBITION OF ENDOTHELIN-1 (ET-1) BY THE DUAL RECEPTOR ANTAGONIST, BOSENTAN, INCREASES MMP-9 EXPRESSION BY SCLERODERMIC FIBROBLASTS IN VITRO</b>  F. IANNONE, R. BIZZOCA, A. CHIALA', E. LANCIANO, G. LAPADULA	<b>155</b>
<b>SP.01.3</b> <b>0</b>	<b>MICROVASCULAR IMPLICATIONS IN SCLERODERMA: TO MODEL THE EFFECTS OF ISCHAEMIA / REPERFUSION IN SCLERODERMA ON EXPRESSION OF FIBROGENIC AGENTS BY ENDOTHELIAL CELLS</b>  S. HOWAT, A. BUISSON, C.P. DENTON, D.J. ABRAHAM, J.D. PEARSON	<b>157</b>
<b>SP.01.3</b> <b>1</b>	<b>DIFFERENTIAL EXPRESSION OF CHI3L1 IDENTIFIES SUBGROUPS OF SCLERODERMA (SSC) PATIENTS</b>  Y. HO, M. Baron, P. Roughley, J. Mort, A. Recklies	<b>159</b>

<b>SP.01.3</b> <b>2</b>	<b>A NOVEL INHIBITOR OF TGF-BETA /SMADS SIGNALING ATTENUATES TISSUE FIBROSIS IN MOUSE MODELS OF SYSTEMIC SCLEROSIS</b>	<b>162</b>
	M. HASEGAWA, Y. Matsushita, M. Horikawa, K. Higashi, Y. Tomigahara, H. Kaneko, F. Shirasaki, M. Fujimoto, K. Takehara, S. Sato	
<b>SP.01.3</b> <b>3</b>	<b>SEMAPHORIN 4D INVOLVEMENT IN SYSTEMIC SCLEROSIS</b>	<b>173</b>
	D. Opris, A. Besliu, R. Ionescu, D. Predeteanu, L. Banica, C. Ghitonu, G. Pistol, M. Stefanescu, C. Matache	
<b>SP.01.3</b> <b>4</b>	<b>TELOMERE LENGTH MEASUREMENT IN LIMITED AND DIFFUSE SYSTEMIC SCLEROSIS (SSC) BY A NOVEL MONOCHROME MULTIPLEX QUANTITATIVE PCR METHOD</b>	<b>176</b>
	T. FRECH, B. Markewitz, N. Hatton, M. Scholand, R. Cawthon, A. Sawitzke	
<b>SP.01.3</b> <b>5</b>	<b>DERMAL FIBROBLASTS FROM OCCUPATIONALLY EXPOSED SCLERODERMA PATIENTS SHOW A DIFFERENTIAL RESPONSE TO CRYSTALLINE SILICA COMPARED TO UNEXPOSED</b>	<b>184</b>
	H. England, A. Herrick, S. Kumar, A. Povey	
<b>SP.01.3</b> <b>6</b>	<b>FIBROBLAST-SPECIFIC ACTIVATION OF TGF-BETA IN MICE RECAPITULATES A HYPOXIC PULMONARY HYPERTENSION PHENOTYPE</b>	<b>202</b>
	E. DERRETT-SMITH, R. Baliga, K. Khan, X. Shi-Wen, D. Abraham, C. Denton	
<b>SP.01.3</b> <b>7</b>	<b>PROTEASOME INHIBITION ENHANCES MMP-1 PRODUCTION VIA C-JUN AND INHIBITS TYPE I COLLAGEN PRODUCTION IN RESPONSE TO TGF-BETA BY INHIBITING SP1 IN HUMAN DERMAL FIBROBLASTS</b>	<b>221</b>
	C. CHIZZOLINI, L. GOFFIN, Q. SEGUIN-ESTEVEZ, M. ALVAREZ, W. REITH	
<b>SP.01.3</b> <b>8</b>	<b>LOSS OF LPA1 SIGNALING PROTECTS AGAINST DERMAL FIBROSIS IN A BLEOMYCIN-INDUCED MOUSE MODEL OF SYSTEMIC SCLEROSIS.</b>	<b>230</b>
	F.V. Castelino(, ), S.F. Brooks, M. Funke, J. Chun, A.D. Luster(, ), A.M. Tager(, )	
<b>SP.01.3</b> <b>9</b>	<b>THERAPEUTIC EFFECT OF THE DIRECT THROMBIN INHIBITOR DABIGATRAN ON LUNG INJURY IN MICE MODEL OF SCLERODERMA PULMONARY FIBROSIS</b>	<b>248</b>
	G. BOGATKEVICH, A. Ludwicks-Bradley, R. Silver	

<b>SP.01.4 0</b>	<b>PRODUCTION OF A PROLIFERATION-INDUCING LIGAND (APRIL) BY THE PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH SYSTEMIC SCLEROSIS</b>	<b>249</b>
	P. BERNATOWICZ, M. BIELECKI, K. KOWAL, A. LAPINSKA, J. SKOWRONSKI, S. SIERAKOWSKI, L. CHYCZEWSKI, O. KOWAL-BIELECKA	
<b>SP.1.41</b>	<b>SYSTEMIC SCLEROSIS SERUM INCREASES ENDOTHELIAL CELL APOPTOSIS AND ACTIVATION IN NEUTROPHIL-ENDOTHELIAL CELL CO-CULTURES: A ROLE FOR INTERLEUKIN 6.</b>	<b>255</b>
	T. BARNES, D. SPILLER, M. ANDERSON, S. EDWARDS, R. MOOTS	
<b>SP.01.4 2</b>	<b>INTRACELLULAR FREE RADICAL PRODUCTION BY PERIPHERAL BLOOD T LYMPHOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS: ROLE OF NADPH OXIDASE AND RAS.</b>	<b>269</b>
	D. AMICO, S. SVEGLIATI, M. ROVINELLI, L. DE GENNARO, C. TONNINI, A. GABRIELLI	
<b>SP.01.4 3</b>	<b>ALTERATION OF TH17 AND TREG CELL SUBPOPULATIONS CO-EXIST IN PATIENTS AFFECTED WITH SYSTEMIC SCLEROSIS</b>	<b>306</b>
	S. NEGRINI, N. PANICO, D. FENOGLIO, F. BATTAGLIA, A. PARODI, S. STRINGARA, M. GHIO, F. INDIVERI, G. FILACI	
<b>SP.01.4 4</b>	<b>PROTEOMIC ANALYSIS OF SERUM STIMULATED SSC PATIENT FIBROBLASTS</b>	<b>309</b>
	M. PALIOURAS, M. TRIFIRO, M. BARON, D. Di Capua	
<b>SP.01.4 5</b>	<b>CANNABINOIDS INHIBIT FIBROGENESIS IN BLEOMYCIN-INDUCED DERMAL FIBROSIS</b>	<b>325</b>
	E. Balistreri, E. Selvi, E. Garcia-Gonzalez, S. Lorenzini, A. Akhmetshina, K. Palumbo, M. Galeazzi, J. Distler	
<b>SP.01.4 6</b>	<b>SURNATANTS FROM SYSTEMIC SCLEROSIS PBMCS CO-CULTURED WITH AUTOLOGOUS FIBROBLASTS DISPLAY HIGH LEVELS OF PRO-FIBROTIC CYTOKINES</b>	<b>335</b>
	E. D'AIUTO, S. Vettori, D. Ranaldi, G. Pasquale, G. Barra, R. De Palma, G. Valentini	
<b>SP.01.4 7</b>	<b>THE ANTI-FIBROTIC EFFECT OF MYCOPHENOLATE MOFETIL OF THROUGH INHIBITING TGF-B-INDUCED ERK PATHWAY IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE</b>	<b>354</b>
	JUNG-YOON. Choe, HYUN-YOUNG. Jung, SUNG-HOON. Park, SEONG-KYU. Kim	

<b>SP.01.4</b>	<b>COMP - a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker</b>	<b>362</b>
<b>8</b>		
	ROGER. Hesselstrand, ANJA. Kassner, DICK. Heinegård, TORE. Saxne	
<b>SP.01.4</b>	<b>EFFECTOR CD8+ T CELLS IN SYSTEMIC SCLEROSIS PATIENTS MAKE ABNORMALLY HIGH LEVELS OF IL-13 ASSOCIATED WITH INCREASED SKIN FIBROSIS</b>	<b>364</b>
<b>9</b>		
	PATRIZIA. Fuschiotti, THOMAS A. Medsger Jr, PENELOPE A. Morel(,)	
<b>SP.01.5</b>	<b>RELAXIN RECEPTOR LGR7 ON NORMAL AND SCLERODERMIC SKIN</b>	<b>368</b>
<b>0</b>		
	N. Giordano, D. Franci, A. Fioravanti, N. Volpi, P. Papakostas, A. Montella, B. Lucani, M. Fimiani, C. Miracco, G. Grasso, M. Galeazzi, R. Nuti	
<b>SP.01.5</b>	<b>MITOCHONDRIAL TRANSMEMBRANE POTENTIAL (??M) IN T CD4+ AND CD8+ LYMPHOCYTES OF SSC PATIENTS</b>	<b>371</b>
<b>1</b>		
	D. Krasowska, M. Szymanek, G. Chodorowska, A. Surdacka	
<b>SP.01.5</b>	<b>IDENTIFICATION OF GENES UNDERLYING SYSTEMIC SCLEROSIS IN THE UCD200 CHICKEN</b>	<b>377</b>
<b>1bis</b>		
	SUSANNE. Kerje(,), ANNA-STINA. Sahlqvist, WERONICA. Ek, OLOV. Ekwall, GEORG. Wick, KAREL. Hala, HERMANN. Dietrich, ROSWITHA. Sgonc, LEIF. Andersson, ÖRJAN. Carlborg, OLLE. Kämpe	
<b>SP.01.5</b>	<b>PRELIMINARY ANALYSIS OF CHINESE PATIENTS WITH SYSTEMIC SCLEROSIS----FROM CHINESE EUSTAR DATABASE</b>	<b>12</b>
<b>2</b>		
	D. XU, MT. LI, Y. HONG, Q. WANG, YN. BAI, N. SONG, XF. ZENG	
<b>SP.01.5</b>	<b>RAPIDLY PROGRESSIVE SYSTEMIC SCLEROSIS WITH A FATAL OUTCOME IN MALE PATIENTS</b>	<b>14</b>
<b>3</b>		
	M. WIDUCHOWSKA, A. Kotulska, M. Kopec-Medrek, M. Glowacka, E.J. Kucharz	
<b>SP.01.5</b>	<b>NUTRITION STATUS AS MARKER FOR DISEASE ACTIVITY AND SEVERITY PREDICTING MORTALITY IN SSC PATIENTS</b>	<b>51</b>
<b>4</b>		
	G. RIEMEKASTEN, L. Krause, C. Brueckner, M. Becker, T. Bellinghausen, C. Becker, U. Schneider, T. Haepl, H. Ebert, U. Mueller-Ladner, G. Burmester	
<b>SP.01.5</b>	<b>INCIDENCE, PREVALENCE AND DISEASE CHARACTERISTICS OF SYSTEMIC SCLEROSIS IN CROATIA</b>	<b>55</b>
<b>5</b>		
	D. Martinovic Kaliterna, M. Radic, J. Morovic Vergles, B. Anic, S. Novak	



<b>SP.01.5 6</b>	<b>THE DEVELOPMENT OF UPDATED CRITERIA FOR SYSTEMIC SCLEROSIS (SSC) USING DELPHI TECHNIQUE AND CLUSTER AND FREQUENCY ANALYSES FROM A LARGE SSC PATIENT DATABASE</b>	<b>58</b>
	J. POPE, C. Coulter, Delphi Consensus Members, M. Baron	
<b>SP.1.57</b>	<b>DIFFERENCES IN DISABILITY AS MEASURED BY THE HAQ AND HAND FUNCTION SCORE FROM DIGITAL ULCERS. AN ANALYSIS OF TWO RCTS.</b>	<b>59</b>
	J. POPE, C. Zelenietz	
<b>SP.01.5 8</b>	<b>BEST PRACTICES IN SSC. ARE GUIDELINES FOLLOWED? RESULTS FROM THE CANADIAN SCLERODERMA RESEARCH GROUP (CSRG)</b>	<b>62</b>
	J. POPE, S. Harding, S. Khimdas, CSRG, M. Baron	
<b>SP.01.5 9</b>	<b>PREVALENCE AND POSSIBLE CAUSES OF RESTLESS LEGS SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS</b>	<b>72</b>
	P. OSTOJIC, B. STOJIC, S. JANJIC, T. JOVIC, M. MANIGODA, S. PETKOVIC, N. DAMJANOV	
<b>SP.01.6 0</b>	<b>THROMBOCYTOSIS AND HIGH SKIN SCORE ASSOCIATE WITH ELEVATED SERUM IL-6 LEVEL IN SYSTEMIC SCLEROSIS</b>	<b>75</b>
	V. ONG, S. Nihtyanova, C. Black, C. Denton	
<b>SP.01.6 1</b>	<b>DESCRIBING ORGAN DAMAGE IN SYSTEMIC SCLEROSIS</b>	<b>77</b>
	M. NIKPOUR, J. BYRON, J. ZOCHLING, M. CHAN, P. NASH, J. SAHHAR, A. STURGESS, K. TYMMS, P. YOUSSEF, S. PROUDMAN(0), W. STEVENS	
<b>SP.01.6 2</b>	<b>SENSITIVITY TO CHANGE IN SYSTEMIC SCLEROSIS OF THE MCMASTER-TORONTO ARTHRITIS PATIENT PREFERENCE DISABILITY QUESTIONNAIRE (MACTAR): SHIFT IN PATIENT PRIORITIES OVER TIME</b>	<b>80</b>
	C. NGUYEN, L. Mouthon, C. Mesre-Stanislas, F. Rannou, A. Bérezné, K. Sanchez, A. Papelard, M. Revel, L. Guillevin, S. Poiraudreau(0)	
<b>SP.01.6 3</b>	<b>EMPLOYMENT STATUS AND BURDEN IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL SURVEY</b>	<b>81</b>
	C. NGUYEN, S. Poiraudreau, C. Mestre-Stanislas, F. Rannou, A. Bérezné, A. Papelard, M. Revel, L. Guillevin, L. Mouthon	

<b>SP.01.6</b>	<b>MODIFICATION OF CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS</b>	<b>85</b>
<b>4</b>	<b>NADASHKEVICH, DAVIS, FRITZLER (2004)</b>	
	O. NADASHKEVICH	
<b>SP.01.6</b>	<b>PARRY-ROMBERG SYNDROME VERSUS SCLERODERMA – CASE REPORT</b>	<b>87</b>
<b>5</b>		
	C. MÜLLER, L.G. FAVRETTO, E.S. PAIVA, V.F. AZEVEDO, S.C. RADOMINSKI	
<b>SP.01.6</b>	<b>A STUDY OF SCLERODERMA IN SOUTH OF BRAZIL: CUTANEOUS</b>	<b>88</b>
<b>6</b>	<b>MANIFESTATIONS AND CLINICAL-LABORATORIAL MARKERS ASSOCIATION.</b>	
	C. MÜLLER, J.H. LIMA FILHO, E.S. PAIVA, V.F. AZEVEDO, S.C. RADOMINSKI	
<b>SP.01.6</b>	<b>ASSESSING ORGAN INVOLVEMENT AND CURRENT SYMPTOMS AS INDICATORS</b>	<b>94</b>
<b>7</b>	<b>FOR DISEASE PROGRESSION IN A 2400 PATIENT COHORT</b>	
	P. MOINZADEH, N. Hunzelmann, A. Fehr, E. Genth, A. Juche, I. Kötter, A. Kreuter, T. Krieg, I. Melchers, M. Meurer, U. Müller-Ladner, G. Riemekasten, C. Sunderkötter(0)	
<b>SP.01.6</b>	<b>CONSTRUCT VALIDITY EVALUATION OF THE EUROPEAN SCLERODERMA STUDY</b>	<b>99</b>
<b>8</b>	<b>GROUP ACTIVITY INDEX, AND INVESTIGATION OF POSSIBLE NEW DISEASE</b>	
	<b>ACTIVITY MARKERS IN SYSTEMIC SCLEROSIS</b>	
	T. Minier, Z. Nagy, Z. Bálint, H. Farkas, J. Judit, G. Kumánovics, T. Czömpöly, D. Simon, C. Varjú, P. Németh, L. Czirják	
<b>SP.01.6</b>	<b>FINGERPRINTS EVALUATION IN SYSTEMIC SCLEROSIS</b>	<b>101</b>
<b>9</b>		
	R. C. Ionitescu, GH. Popa, C. Mihai, R. Potorac, R. Sfrent-Cornateanu, M. Bojinca, V. Stoica	
<b>SP.01.7</b>	<b>CANCER PREVALENCE IN ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS</b>	<b>108</b>
<b>0</b>		
	B. MARASINI, L. BELLOLI, N. CARLO-STELLA	
<b>SP.01.7</b>	<b>SYSTEMIC SCLEROSIS AND SILICA EXPOSURE: A RARE ASSOCIATION IN A LARGE</b>	<b>113</b>
<b>1</b>	<b>BRAZILIAN COHORT</b>	
	L.F. ROCHA, R.G. MARANGONI, A.P.T. DEL RIO, N.H. YOSHINARI, J.F. MARQUES-NETO, P.D. SAMPAIO-BARROS	
<b>SP.01.7</b>	<b>SYSTEMIC SCLEROSIS SINE SCLERODERMA: ANALYSIS OF 60 PATIENTS.</b>	<b>114</b>
<b>2</b>		
	R.G. MARANGONI, L.F. ROCHA, A.P.T. DEL RIO, N.H. YOSHINARI, J.F. MARQUES-NETO, P.D. SAMPAIO-BARROS	

<b>SP.01.7 3</b>	<b>CLINICAL AND HISTOPATHOLOGIC COMPARISON OF GENERALIZED SUBCUTANEOUS MORPHEA (GSM) WITH EOSINOPHILIC FASCIITIS (EF)</b>	<b>117</b>
	F. MAHMOOD, A. Impens, E. Schiopu, K. Phillips, L. Lowe, S. Olsen, J. Seibold	
<b>SP.01.7 4</b>	<b>VALIDATION OF THE ENTERPRISE DATA WAREHOUSE APPROACH TO SEARCHING AN ESTABLISHED SYSTEMIC SCLEROSIS PATIENT REGISTRY AND BIOREPOSITORY</b>	<b>160</b>
	M. HINCHCLIFF, M. Carns, S. Podluszky, N. Kieffer, A. Parameswaran, E. Just, J. Varga	
<b>SP.01.7 5</b>	<b>CONSTRUCT VALIDITY, FEASIBILITY AND ACCEPTABILITY OF EQ-5D TO ASSESS PHYSICAL AND MENTAL QUALITY OF LIFE IN SYSTEMIC SCLEROSIS PATIENTS</b>	<b>169</b>
	R. GUALTIEROTTI, L. SCALONE, F. INGEGNOLI, S. ZENI, P. CORTESI	
<b>SP.01.7 6</b>	<b>CLINICAL CORRELATIONS OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS</b>	<b>172</b>
	M. GROSEANU, A. Daraban, A. Balanescu, V. Bojinca, D. Predeteanu, C. Constantinescu, M. Negru, D. Opris, F. Berghea, I. Oprisan, R. Ionescu	
<b>SP.01.7 7</b>	<b>UPDATE OF THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM.</b>	<b>181</b>
	I. FOELDVARI, T. Avcin, K. Minden, C. Len, L. Mouthon, J. Brunner, Y. Uziel, J.- Müller, A. Wierk	
<b>SP.01.0 78</b>	<b>CORRELATION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX WITH LUNG PARAMETERS IN SYSTEMIC SCLEROSIS</b>	<b>182</b>
	I. FILIPESCU, C. Pamfil, L. Poanta, M. Man, S. Rednic	
<b>SP.01.7 9</b>	<b>HEALTH RELATED QUALITY OF LIFE OF SYSTEMIC SCLEROSIS IN MIDDLE EASTERN SOCIETY: A CROSS SECTIONAL SURVEY</b>	<b>187</b>
	D. EL-HAMMADY, N. Fathy	
<b>SP.01.8 0</b>	<b>CLINICAL COURSE AND OUTCOME OF SYSTEMIC SCLEROSIS OVERLAP SYNDROME.</b>	<b>200</b>
	O. DESINOVA	
<b>SP.01.8 1</b>	<b>VALIDITY AND RELIABILITY OF THE ITALIAN VERSION OF THE MOUTH HANDICAP IN SYSTEMIC SCLEROSIS SCALE (MHISS)</b>	<b>207</b>
	A. DEL ROSSO, S. Maddali-Bongji, I. Miniati, F. Galluccio, G. Landi, G. Tai, M. Matucci Cerinic	

<b>SP.01.8</b>	<b>ASSESSMENT OF RESPIRATORY MUSCLE STRENGTH IN PATIENTS WITH SYSTEMIC SCLEROSIS</b>	<b>211</b>
<b>2</b>	A. P. DEL RIO, C. S. BORGES, E. MAGALHÃES, P. D. SAMPAIO-BARROS, J. P. C. MATHEUS, S. REZENDE, M. B. BÉRTOLO, J. F. MARQUES NETO	
<b>SP.01.8</b>	<b>PREVALENCE OF SYSTEMIC SCLEROSIS IN LORRAINE, FRANCE, USING A CAPTURE-RECAPTURE METHOD.</b>	<b>214</b>
<b>3</b>	J. DE KORWIN, D. CIRSTEÀ, J.M. VIRION, D. IBBA-MULLER, F. GUILLEMIN	
<b>SP.01.8</b>	<b>ORAL HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS.</b>	<b>219</b>
<b>4</b>	F.P. COSTA, C. SOBRAL, L.B. MASSAI, J.F. MARQUES-NETO, P.D. SAMPAIO-BARROS, L.H. D'OTTAVIANO	
<b>SP.01.8</b>	<b>SYSTEMIC SCLEROSIS – CASE REVIEW OF 15 PORTUGUESE PATIENTS AND DISCUSSION ON CLASSIFICATION CRITERIA AND ORGAN INVOLVEMENT</b>	<b>235</b>
<b>5</b>	I. CÂMARA, J. MATOS COSTA, R. PAULOS, J. PARENTE, J. P. ANDRADE, C. SANTOS, F. CARRILHO, L. SIOPA	
<b>SP.01.8</b>	<b>SCLERODERMA OVERLAP SYNDROME</b>	<b>240</b>
<b>6</b>	A. BALBIR-GURMAN, AM. NAHIR, Y. BRAUN-MOSCOVICI	
<b>SP.01.8</b>	<b>SYSTEMIC SCLEROSIS AND CANCER: A NATIONWIDE FOLLOW UP STUDY FROM DENMARK</b>	<b>242</b>
<b>7</b>	A. BRAAE OLESEN, C. Sværke, D. Körmendiné Farkas, H. Toft Sørensen	
<b>SP.01.8</b>	<b>PREVALENCE OF METABOLIC SYNDROME AND CARDIOVASCULAR RISK FACTORS IN SYSTEMIC SCLEROSIS</b>	<b>262</b>
<b>8</b>	M. ANTIVALLE, A. MUTTI, M. BATTELLINO, A. BATTICCIOTTO, L. BERTANI, F. ATZENI, P. SARZI-PUTTINI	
<b>SP.01.8</b>	<b>ERASMUS SYNDROME: A REPORT OF 2 CASES</b>	<b>268</b>
<b>9</b>	S. Anandan, S. Shobana, MA. Suprabha, R. Sudha, TP. Vetrichevvel, L. Renita	
<b>SP.01.9</b>	<b>INTEROBSERVER AND INTRAOBSERVER RELIABILITY OF THE MODIFIED RODNAN SKIN SCORE IN SYSTEMIC SCLEROSIS. RESULTS FROM A-SINGLE-CENTER STUDY</b>	<b>274</b>
<b>0</b>	J. ALEGRE SANCHO, J.M. Senabre Gallego, E. Beltran Catalan, F. Gil Latorre, J.A. Roman Ivorra, J. Ivorra Cortes, C. Chalmeta Verdejo, N. Fernandez Llanio, S. Muñoz Gil, E. Valls Pascual, I. Martinez Cordellat	

<b>SP.01.9</b> <b>1</b>	<b>INTEROBSERVER WITHIN-PATIENT VARIABILITY OF THE MODIFIED RODNAN SKIN SCORE IN SYSTEMIC SCLEROSIS. RESULTS FROM A SPANISH LOCAL TEACHING COURSE</b>	<b>275</b>
	J. ALEGRE SANCHO, J.A. Román Ivorra, E. Beltrán Catalán, E. Valls Pascual, C. Chalmeta Verdejo, N. Fernández Llanio, J. Ivorra Cortés, F. Gil Latorre, J.M. Senabre Gallego, S. Muñoz Gil, I. Martinez Cordellat	
<b>SP.01.9</b> <b>2</b>	<b>SURVIVAL AND DEATH CAUSES IN 251 SYSTEMIC SCLEROSIS PATIENTS FROM A SINGLE ITALIAN CENTER</b>	<b>287</b>
	S. VETTORI, G. CUOMO, G. ABIGNANO, M. IUDICI, G. VALENTINI	
<b>SP.01.9</b> <b>3</b>	<b>EVALUATION OF SKIN INVOLVEMENT IN SSC PATIENTS WITH MODIFIED RODNAN SKIN SCORE: RESULTS OF THE ITALIAN COURSE</b>	<b>311</b>
	I. MINIATI, G. VALENTINI, F. COZZI, S. GUIDUCCI, G. CUOMO, S. VETTORI, C. BONINO, L. CIPRIAN, N. PANICO, M. MATUCCI CERINIC, L. CZIRJAK	
<b>SP.01.9</b> <b>4</b>	<b>PARENT AND CHILDREN'S BELIEFS ABOUT CHILDHOOD ONSET SCLERODERMA</b>	<b>330</b>
	H. ENNIS, AL. HERRICK, E. BAILDAM, HL. RICHARDS	
<b>SP.01.9</b> <b>5</b>	<b>EUROPEAN SCLERODERMA ACTIVITY INDEX IS CORRELATED TO QUALITY OF LIFE AS ASSESSED BY SHORT FORM-36 (SF-36)</b>	<b>336</b>
	G. CUOMO, M. Iudici, G. Abignano, A. Petrillo, G. Valentini	
<b>SP.01.9</b> <b>6</b>	<b>INCIDENCE AND PREVALENCE OF SYSTEMIC SCLEROSIS (SSC) IN AN HMO IN ARGENTINA</b>	<b>340</b>
	L. CATOGGIO, ER. Soriano(,), JE. Rosa(,), L. Narvaez Ponce(,), C. Castel del Cid(,), PM. Imamura(,)	
<b>SP.01.9</b> <b>7</b>	<b>MIXED CONNECTIVE TISSUE DISEASE (MCTD): ONE DIAGNOSIS, MORE EVOLUTIONS</b>	<b>342</b>
	S. CAPPELLI, S. BELLANDO RANDONE, D. MARTINOVIC, M. RADIC, S. REDNIC, M.M. TAMAS, N. DAMJANOV, K. PASALIC, Y. ALLANORE, S. BOMBARDIERI, M. MOSCA, R. TALARICO, R. IONESCU, D. OPRIS, L. CZIRJAK, C. KISS, M. ARINGER, A.K. TAUSCHE, F. COZZI(0), M.M. MATUCCI CERINIC	
<b>SP.01.9</b> <b>8</b>	<b>OUTCOME AND CAUSES OF DEATH IN SYSTEMIC SCLEROSIS - A SOUTH AFRICAN EXPERIENCE</b>	<b>351</b>
	M. TIKLY, N. Jabaar, E. Musenge	

<b>SP.01.9 9</b>	<b>FATIGUE SEVERITY CORRELATES WITH MODIFIABLE PSYCHOSOCIAL VARIABLES IN EARLY SYSTEMIC SCLEROSIS</b>	<b>363</b>
	ASTRUD. Leyva, SHERVIN. Assassi, DEEPTHI. Nair, MICHAEL. Fischbach, HILDA. Draeger, FRANK C. Arnett, JOHN D. Reveille, MAUREEN D. Mayes, EMILIO B. Gonzalez, TERRY A. McNearney	
<b>SP.01.1 00</b>	<b>SYSTEMIC SCLEROSIS : A LATIN-AMERICAN STUDY IN COLOMBIA AND ARGENTINA, CLINICAL, IMMUNOLOGICAL AND ORGAN INVOLVEMEN</b>	<b>373</b>
	P. Corral, J. Scali	
<b>SP.01.1 01</b>	<b>THE SIX-MINUTE WALK TEST IN SYSTEMIC SCLEROSIS</b>	<b>22</b>
	M. VONK, F. van den Hoogen, J. Fransen, P. Dekhuizen, P. van Riel, Y. Heijdra	
<b>SP.01.1 02</b>	<b>THE DETECT STUDY: A TWO-STAGE, PROSPECTIVE, OBSERVATIONAL, COHORT STUDY IN SCLERODERMA PATIENTS TO EVALUATE SCREENING TESTS AND THE INCIDENCE OF PULMONARY HYPERTENSION</b>	<b>24</b>
	M. VONK, G. Coghlan, D. Bonderman, C. Denton, O. Distler, E. Grunig, D. Khanna, V. McLaughlin, U. Muller-Ladner, J. Pope, J. Seibold	
<b>SP.1.10 3</b>	<b>PULMONARY HYPERTENSION ASSESSMENT AND RECOGNITION OF OUTCOMES IN SCLERODERMA (PHAROS): TWO-YEAR OUTCOMES FOR PATIENTS WITH PULMONARY HYPERTENSION</b>	<b>37</b>
	L. Chung, V. Steen, PHAROS investigators	
<b>SP.01.1 04</b>	<b>PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS- CORRELATION WITH DISEASE DURATION AND SEVERITY, CAPILLARY CHANGES AND PULMONARY FIBROSIS</b>	<b>39</b>
	B. STAMENKOVIC, A. Stankovic, J. Nedovic, S. Stojanovic, A. Dimic, D. Djordjevic	
<b>SP.01.1 05</b>	<b>CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF JAPANESE PATIENTS WITH CONNECTIVE TISSUE DISEASE AND PULMONARY ARTERIAL HYPERTENSION</b>	<b>42</b>
	Y. SHIRAI, H. YASUOKA, T. TAKEUCHI, T. SATOH, M. KUWANA	
<b>SP.01.1 06</b>	<b>SERUM LEVELS OF ENDOGLIN IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ISOLATED PULMONARY ARTERIAL HYPERTENSION</b>	<b>66</b>
	C. PAOLA XIMENA, MF. GARCES, E. CAMINOS, A. IGLESIAS, JF. RESTREPO, G. QUINTANA	

<b>SP.01.1 07</b>	<b>INCREASED INTERSTITIAL INFLAMMATORY CELL INFILTRATION, BUT NOT FIBROSIS, IN RIGHT VENTRICLES OF SSC-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH) VS. IDIOPATHIC PAH</b>	<b>68</b>
	M. OVERBEEK, K. MOUCHAERS, H. NIESSEN, K. KUPREISHVILI, A. BOONSTRA, A. VOSJUYL, J. BELIEN, E. SMIT, B. DIJKMANS, A. VONK NOORDEGRAAF, K. GRUNBERG	
<b>SP.01.1 08</b>	<b>PDGFR-<math>\alpha</math> AND EGFR IN PULMONARY VASCULATURE OF SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH) VS. IDIOPATHIC PAH</b>	<b>69</b>
	M. OVERBEEK, A. BOONSTRA, A. VOSKUYL, M. VONK, A. VONK NOORDEGRAAF, M. VAN BERKEL, W. MOOI, B. DIJKMANS, E. SMIT, K. GRUNBERG	
<b>SP.01.1 09</b>	<b>PULMONARY ARTERIAL HYPERTENSION IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: A DISTINCTIVE VASCULOPATHY</b>	<b>70</b>
	M. OVERBEEK, M. VONK, A. BOONSTRA, A. VOSKUYL, A. VONK NOORDEGRAAF, E. SMIT, B. DIJKMANS, W. MOOI, Y. HEIJDRRA, K. GRUNBERG	
<b>SP.01.1 10</b>	<b>THE KOREAN REGISTRY OF PULMONARY HYPERTENSION ASSOCIATED WITH THE RHEUMATIC DISEASES; THE REOPHARD STUDY</b>	<b>147</b>
	J. JUN, C. Jeon, J. Chai, Y. Seo, E. Koh	
<b>SP.01.1 11</b>	<b>THE DATABASE FOR SYSTEMIC SCLEROSIS IN TURKEY (SYS-WATCH): ANALYSIS OF PATIENTS WITH ELEVATED PULMONARY ARTERIAL PRESSURES ON ECHOCARDIOGRAPHIC SCREENING FOR PULMONARY HYPERTENSION</b>	<b>151</b>
	M. INANÇ, M. BIRLIK, A.M. ONAT, Z. OZBALKAN, F. YARGUCU, T. KASIFOGLU, O.N. PAMUK, V. YAZISIZ, S. YAVUZ, D. ARSLAN(0), A. ATES, E. ERKEN(0)	
<b>SP.01.1 12</b>	<b>PULMONARY HYPERTENSION ASSESSMENT AND RECOGNITION OF OUTCOMES IN SCLERODERMA (PHAROS): UTILITY OF SIX MINUTE WALK TEST</b>	<b>153</b>
	A. IMPENS, M. Hinchcliff, L. Hummers, M. Mayes, C. Derk, L. Shapiro, R. Domsic, B. Segal, A. Goldberg, F. Alkassab, V. Steen, and the PHAROS Investigat	
<b>SP.01.1 13</b>	<b>PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS IN PATIENTS WITH FUNCTIONAL CLASS II DYSPNOEA: MILD SYMPTOMS BUT SEVERE OUTCOME</b>	<b>167</b>
	E. HACHULLA, D. LAUNAY, A. YAICI, A. BEREZNE, P. de GROOTE, O. SITBON, L. MOUTHON, L. GUILLEVIN, P.Y. HATRON, G. SIMONNEAU(0), P. CLERSON(0), M. HUMBERT	
<b>SP.01.1 14</b>	<b>THE PREVALENCE OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS PATIENTS SCREENED WITH RIGHT HEART CATHETERISATION.</b>	<b>188</b>
	N. DWYER, J. WALSH, D. KILPATRICK(,), J. ZOCHLING	

<b>SP.01.1</b> <b>15</b>	<b>EXERCISE-INDUCED ARTERIAL PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS. AN ECHOCARDIOGRAPHY STUDY.</b>	<b>217</b>
	V. Degani, P. Piovesana, E. Pigatto, F. D'Ambrosio, S. Cardarelli, M.G. Leone, M. Rizzo, V. Scarabeo, L. Ciprian, F. De Conti, F. Cozzi	
<b>SP.01.1</b> <b>16</b>	<b>PULMONARY HYPERTENSION IN PATIENTS WITH SCLERODERMA: CORRELATIONS TO PULMONARY FUNCTION TESTING AND EXERCISE PARAMETERS</b>	<b>243</b>
	AK. Boutou, P. Siakka, T. Dimitroulas, T. Sfetsios, G. Pitsiou, N. Chavouzis, P. Argyropoulou, A. Garyfallos, I. Stanopoulos	
<b>SP.01.1</b> <b>17</b>	<b>HEAD TO HEAD COMPARISON OF BRAIN NATRIURETIC PEPTIDE AND NT-PROBNP IN THE SCREENING OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS PATIENTS</b>	<b>245</b>
	C. BONINO, L. CAVAGNA, R. CAPORALI, S. GHIO, R. ALBERTINI, R. MORATTI, C. KLERSY, C. MONTECUCCO	
<b>SP.01.1</b> <b>18</b>	<b>EPIDEMIOLOGICAL STUDY OF PULMONARY ARTERIAL HYPERTENSION RELATED TO SYSTEMIC SCLEROSIS IN THE CZECH REPUBLIC</b>	<b>251</b>
	R. BECVAR, P. JANSKA, J. STORK, D. AMBROZ, J. MARESOVA, T. PALECEK, M. TOMCIK, A. LINHART	
<b>SP.01.1</b> <b>19</b>	<b>POINT PREVALENCE OF PULMONARY HYPERTENSIONS IN SYSTEMIC SCLEROSIS: RESULTS FROM TWO LARGE COHORTS (OF EUROPEAN CAUCASIAN PATIENTS) AND META-ANALYSIS.</b>	<b>258</b>
	J. AVOUAC, P. Airò, C. Meune, L. Beretta, P. Dieude, P. Caramaschi, K. Tiev, S. Cappelli, E. Diot, A. Vacca, JL. Cracowski, J. Sibilia(0), A. kahan, M. Matucci-Cerinic, Y. Allanore	
<b>SP.01.1</b> <b>20</b>	<b>ESTIMATED SYSTOLIC PULMONARY ARTERY PRESSURE VERSUS TRICUSPID REGURGITANT JET VELOCITY AS SCREENING TOOLS FOR PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS: THE PHAROS EXPERIENCE</b>	<b>272</b>
	F. ALKASSAB, V. Steen, The PHAROS investigators	
<b>SP.01.1</b> <b>21</b>	<b>THE EPIDEMIOLOGY OF SCLERODERMA AND SECONDARY PULMONARY HYPERTENSION IN TASMANIA, AUSTRALIA</b>	<b>285</b>
	J. ZOCHLING, P. LEWIS, J. BYRON, D. LANGSFORD, J. WALSH, N. DWYER, D. KILPATRICK	
<b>SP.01.1</b> <b>22</b>	<b>SYSTEMIC SCLEROSIS PATIENTS WITH AND WITHOUT PULMONARY ARTERIAL HYPERTENSION: A NAILFOLD CAPILLAROSCOPY SURVEY</b>	<b>300</b>
	V. RICCIERI, M. VASILE, V. MACRI', I. SCIARRA, K. STEFANANTONI, C.D. VIZZA, R. BADAGLIACCA, R. POSCIA, E. CRESCENZI, G. VALESINI	

<b>SP.01.1</b> <b>23</b>	<b>PROGNOSTIC ROLE OF ECG IN PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS (SSC)</b>	<b>305</b>
	K. PHILLIPS, C. Byrne-Dugan, E. Schiopu, A. Impens, F. Mahmood, J. Seibold	
<b>SP.01.1</b> <b>24</b>	<b>ANTI-VASCULAR SMOOTH MUSCLE CELLS ANTIBODIES ARE PRESENT IN THE SERUM OF PATIENTS WITH SYSTEMIC SCLEROSIS WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION (PAH) AND IDIOPATHIC PAH PATIENTS</b>	<b>310</b>
	C. Calzas, Y. Sahbatou, G. Bussone, C. Broussard, B. Weksler, A. Yaici, H. Dib, L. Guillevin, M. Humbert, L. Mouthon(0)	
<b>SP.01.1</b> <b>25</b>	<b>DETECTION OF “LATENT” PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC): THE USEFULNESS OF NON INVASIVE ECHOCARDIOGRAPHY</b>	<b>343</b>
	J. BLAGOJEVIC, F. PALLINI, F. PERUZZI, G. FIORI, ML. CONFORTI, A. PESCI, L. ZANASI, A. MOGGI PIGNONE, M. MATUCCI CERINIC	
<b>SP.01.1</b> <b>26</b>	<b>BOSENTAN FOR EXERCISE INDUCED PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: RESULTS FROM AN OPEN STUDY</b>	<b>344</b>
	J. BLAGOJEVIC, F. PALLINI, F. PERUZZI, A. PESCI, L. ZANASI, A. MOGGI PIGNONE, M. MATUCCI CERINIC	
<b>SP.01.1</b> <b>27</b>	<b>SURVIVAL IN PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE TREATED WITH ILOPROST OR TREPOSTINIL</b>	<b>358</b>
	C.J. Valerio, C. Handler, C.P. Denton, J.G. Coghlan	